References
- Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
- Dale D, Crawford J, Lyman G. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidenced-based review. Proc Am Soc Clin Oncol 2001; 20: 410A
- Gómez H, Hidalgo M, Casanova L, Colomer R, Pen D LK, Otero J, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998; 16: 2065–2069
- Lyman G H, Morrison V A, Dale D C, Crawford J, Delgado D J, Fridman M, for the OPPS Working Group and the ANC Study Group. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069–2076
- Morrison V A, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2: 47–56
- Picozzi V J, Pohlman B L, Morrison V A, Lawless G D, Lee M W, Kerr R O, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology 2001; 15: 1296–1306
- Chrischilles E A, Link B K, Scott S D, Delgado D J, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 2003; 10: 396–403
- Weiner N, Fridman M, Steinberg D, Sparks J, Larsen C, Tronic B, et al. A model to predict chemotherapy related neutropenic events in intermediate and high grade lymphoma (IHL) patients (Pts). Blood 1998; 92: 88A
- Morrison V A, Condon D L, Delgado D J, Fridman M. Risk of first febrile neutropenia hospitalization (FNH) among patients receiving chemotherapy for intermediate-grade non-Hodgkin's lymphoma (IG-NHL). Presented at the Eighth Congress of the European Hematology Association. Lyon, France 1315 June, 2003, Abstract 019
- Lyman G H, Delgado D J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402–2409
- Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37: 351–360
- Voelker M D, Rubenstein L M, Chrischilles E A, Chen-Hardee S S, Link B K, Wright K B, et al. Time to first neutropenia hospitalization during first course chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: National SEER–Medicare Study. Blood 2003; 102: 253A
- Silber J H, Fridman M, DiPaola R S, Erder M H, Pauly M V, Fox K R. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early stage breast cancer therapy. J Clin Oncol 1998; 16: 2392–2400
- Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242